Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Massachusetts

Peptide legality · Massachusetts · updated 2026-09-21

Are peptides legal in Massachusetts?

Gray area

Peptides sit in a gray zone in Massachusetts: FDA-approved peptide drugs are legal with a valid prescription, patient-specific compounding is permitted through a licensed pharmacy, but unapproved research peptides remain unlawful and Massachusetts enforces sterile-compounding rules that run stricter than the federal baseline.

Legal status overview

Peptides sit in a gray zone in Massachusetts. FDA-approved peptide medicines such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal when prescribed by a licensed clinician, and a Massachusetts-licensed 503A pharmacy may prepare patient-specific compounds, though compounded medications are not FDA-approved, not a generic, and not evaluated by the FDA. Peptides sold as research-use-only chemicals for human use are unapproved drugs and are not lawful. Massachusetts layers additional inspection, accreditation, and quality requirements on top of the federal floor and is regarded as one of the more restrictive states for compounding.

Key points

  • FDA-approved peptide drugs, including Wegovy® (semaglutide), Ozempic® (semaglutide), and Zepbound® (tirzepatide), are legal in Massachusetts when dispensed under a valid prescription from a licensed prescriber. [3]
  • The Massachusetts Board of Registration in Pharmacy licenses and inspects compounding pharmacies and sets sterile-compounding standards for peptides and injectables prepared or shipped into the state. [1]
  • Patient-specific compounding by a licensed 503A pharmacy remains permitted, but any compounded peptide is not FDA-approved, not a generic, and not evaluated by the FDA. [2]
  • Large-scale, essentially-a-copy compounding of GLP-1 drugs is no longer allowed after the FDA declared the shortages resolved, with tirzepatide off the shortage list in October 2024 and semaglutide in February 2025. [3]
  • BPC-157 was removed from the FDA Category 2 bulk-substances list in April 2026 but was not added to Category 1, so it is not an eligible bulk substance for Section 503A compounding and remains in regulatory limbo. [6]
  • The FDA continued evaluating BPC-157 (free base) and BPC-157 acetate at its July 2026 Pharmacy Compounding Advisory Committee meeting after the original nominations were withdrawn. [4]
  • Massachusetts is repeatedly grouped with the strictest states, imposing inspection, accreditation, and testing requirements above the federal minimum, a posture traced to the state's compounding history. [5]
  • A valid prescriber-patient relationship, which may be established via telehealth for non-controlled products, is required before any compounded peptide is dispensed. [7]

Compound-by-compound status

BPC-157
Restricted
Unapproved new drug. Removed from FDA Category 2 in April 2026 but not placed in Category 1, so it is not eligible for Section 503A compounding. Not FDA-approved, not a generic, and not evaluated by the FDA.
GLP-1 class (semaglutide, tirzepatide)
Legal
Branded FDA-approved products such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal with a prescription. Compounded GLP-1 preparations are limited to documented patient-specific need now that the shortages are resolved, and are not FDA-approved, not a generic, and not evaluated by the FDA.
TB-500 (thymosin beta-4)
Illegal
Unapproved new drug with no FDA-approved human indication. Marketing or selling it for human use, including as a research chemical, is unlawful.
Growth hormone / somatropin
Legal
A prescription drug legal only for FDA-approved indications under a valid prescription. Federal law separately restricts distribution of human growth hormone outside approved medical uses.

Frequently asked questions

Is it legal to get a GLP-1 peptide prescription in Massachusetts?

Yes. FDA-approved GLP-1 medicines such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal when prescribed by a licensed clinician after a valid evaluation. This is information, not medical advice.

Can a Massachusetts pharmacy still compound semaglutide?

Only in limited, patient-specific situations documented by a prescriber, because the FDA has declared the GLP-1 shortages resolved. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA.

Is BPC-157 legal in Massachusetts?

BPC-157 is an unapproved drug. Its April 2026 removal from FDA Category 2 did not make it eligible for compounding under Section 503A, so it remains in a regulatory gap rather than cleared for clinical use.

Are research-use-only peptides legal to buy for personal use?

No. Peptides labeled research-use-only are unapproved drugs, and selling or using them for human consumption is not lawful.

Why is Massachusetts considered stricter than other states?

Massachusetts adds inspection, accreditation, and quality-testing requirements above the federal floor for sterile compounding, placing it among the more restrictive states.

General information based on the sourced research above, not legal advice. For a specific situation in Massachusetts, consult a licensed attorney familiar with pharmaceutical law.